Affiliations: Programa de Pós-Graduação em Ciências
Genômicas e Biotecnologia, Universidade Católica de Brasília,
Brasília, DF, Brazil | Programa de Pós-Graduação em Patologia
Molecular, Universidade de Brasília, Brasília, DF, Brazil
Note: [] Corresponding author: Programa de Pós-Graduação em
Ciências Genômicas e Biotecnologia, Universidade Católica de
Brasília, SGAN 916 Norte, Av. W5 – Módulo B, Bloco C, Sala 207,
Brasília, DF, Brazil – CEP 70790-160. Tel.: +55 61 3448 7222; Fax: +55 61
3347 4797; E-mail: rinaldo.pereira@catolica.edu.br
Abstract: This study aimed to evaluate in the Brazilian population, the
genotypes and population frequencies of pharmacogenetic polymorphisms involved
in the response to drugs used in treatment of acute lymphoblastic leukemia
(ALL), and to compare the data with data from the HapMap populations. There was
significant differentiation between most population pairs, but few associations
between genetic ancestry and SNPs in the Brazilian population were observed.
AMOVA analysis comparing the Brazilian population to all other populations
retrieved from HapMap pointed to a genetic proximity with the European
population. These associations point to preclusion of the use of genetic
ancestry as a proxy for predicting drug response. In this way, any study aiming
to correlate genotype with drug response in the Brazilian population should be
based on pharmacogenetic SNP genotypes.
